Cholesterol drug may boost immunotherapy in Hard-to-Treat stomach cancer
NCT ID NCT07621562
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding a cholesterol-lowering drug (Tafolecimab) to standard immunotherapy (Sintilimab) and chemotherapy (SOX) can shrink tumors in 30 people with advanced pMMR/MSS gastric cancer, a type that usually doesn't respond well to immunotherapy alone. The study is exploratory and aims to see if the combination is safe and effective enough to warrant larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tafolecimab (PCSK9 inhibitor), Sintilimab (PD-1 inhibitor), and SOX chemotherapy (S-1 and Oxaliplatin)
What this could lead to
If successful, this could point toward a new treatment option for the most common type of advanced gastric cancer, which currently responds poorly to immunotherapy alone.
What could go wrong
This is a very early, small (30 people), single-arm exploratory study. It may not show enough benefit to justify larger trials, and the combination could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
he First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••